Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Just as we're about to celebrate what I consider the seventh anniversary of the smartphone -Apple Inc. (Nasdaq: AAPL) launched the iPhone on June 29, 2007 - there's no shortage of "experts" who will tell you the category is already dead.
Ever since Samsung and Apple began warning of a slowdown in smartphone growth about a year ago, the gloom-and-doomers have been writing eulogies for the seemingly ubiquitous product.
For instance, Investor's Business Daily recently said the market is "maturing" - concluding that formerly special devices like the iPhone and the Samsung Galaxy have reached "commodity" status.
Just a few months ago, TheStreet.com said the market is "rapidly losing its growth" and predicted an even more drastic slowdown to come because of the sputtering Western European economy.
And earlier this year, market research firm IDC predicted a slowdown in worldwide smartphone shipments.
These predictions are way off target.
And I can prove it.
The experts study the smartphone-wielding crowds in cafés, airport terminals, sporting events, hotel lobbies, and even supermarkets here in the United States and conclude the market has reached the saturation point.
That's not actually the case.
Besides, there are huge swaths of the world where most folks have yet to even hold a smartphone, let alone own one.
And this means there's still a huge opportunity for global sales.
The IDC report I just mentioned actually shows this. The market-researcher estimates that smartphones sales hit roughly 1 billion units for the first time last year. And by 2018, it is projecting that worldwide sales will zoom to 1.7 billion devices.
We're talking about a market that's going to zoom 70% in just five years.
And we've just identified the biggest beneficiary.
It's a tech leader - a company that has a stranglehold lead on a smartphone component that will make this growth possible. And it just keeps adding to its product offerings and bolstering its technology to maintain its lead and keep its challengers in the rear-view mirror.
Best of all: It's a stock we believe will double in price over the next few years.
It's one of the best investments in tech - and it's one you want to grab now, before Wall Street gets wise.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.
